Theresa Heah, MD

Theresa Heah, MD

President & Chief Medical Officer, Kriya Ophthalmology

  • Bio
    Theresa Heah is the Chief Medical Officer and President for Kriya Ophthalmology. She was most recently the Chief Medical Officer, EVP Operations for AsclepiX Therapeutics where she was responsible for the business strategy, Series A financing, R&D, clinical development, and regulatory strategy to advance the robust pipeline and leading the company in bringing innovative ophthalmology and oncology products to market. Prior to joining AsclepiX Therapeutics, Dr. Heah served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), where she worked on developing gene therapies in ophthalmology and rare diseases. In addition to her clinical experience as an ophthalmologist, Theresa brings over two decades of Global Pharmaceutical Leadership experience, including in the core business area of ophthalmology drug development and commercialization in early-stage private-staged companies (Fovea Pharmaceuticals, AsclepiX Therapeutics), public-staged (Aerie Pharmaceuticals, Allergan) and big pharmaceuticals (Bayer Healthcare, Sanofi). She has a diverse leadership perspective across Clinical, R&D, Medical Affairs, Marketing and Business Development. Under Theresa’s leadership, she led global ophthalmic innovation with multiple successful regulatory submissions in U.S. (7 INDs, 4 NDAs: Ozurdex®, EYLEA®, Rhopressa® & Rocklatan®), Europe and Japan. While at Bayer, she launched EYLEA® successfully into a blockbuster drug. Dr. Heah received her Doctorate of Medicine from Guy’s Kings and St. Thomas’ School of Medicine, King’s College, University of London, and her Executive Master’s in Business Administration from the European School of Management & Technology (ESMT), Berlin.